TapewireFind a company

person · Reporting owner

Santel Donald J

Disclosed activity across 3 companies

Tapewire entity
90159
SEC CIK
0001293630

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Jade Biosciences, Inc.AVTE · Entity 4757DirectorJune 05, 2024June 07, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Jade Biosciences, Inc.

Report date June 05, 2024 · Filed June 07, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2034-06-04Direct12,500 Reported balance After 2024-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-06-05 · Grant · Acquired 12,500 · Balance 12,500

F1: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Oyster Point Pharma, Inc.

Report date January 03, 2023 · Filed January 04, 2023

Section 16 reporting ended · disclosed 2023-01-04. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2023-01-03 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2023-01-03 · Other · Disposed 5,489 · Balance 8,198

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2)

F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.

Row 2 · 2023-01-03 · Disposition to issuer · Disposed 8,198 · Balance 0

F3: This line item represents restricted stock units held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested restricted stock units was accelerated and each restricted stock unit was canceled in exchange for a cash payment equal to the Per Share Price less applicable tax withholdings.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.25 · Expires 2031-07-30Direct0 Reported balance After 2023-01-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-01-03 · Disposition to issuer · Disposed 15,170 · Balance 0

F5: Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.

F4: This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.63 · Expires 2032-06-05Direct0 Reported balance After 2023-01-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-01-03 · Disposition to issuer · Disposed 5,359 · Balance 0

F5: Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.

F4: This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2)

F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.

F3: This line item represents restricted stock units held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested restricted stock units was accelerated and each restricted stock unit was canceled in exchange for a cash payment equal to the Per Share Price less applicable tax withholdings.

F4: This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.

F5: Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.

Surrozen, Inc./DE

Report date August 11, 2021 · Filed August 13, 2021

Section 16 reporting ended · disclosed 2021-08-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect30,000 Reported balance After 2021-08-11 transaction · row 1
1 source row

Row 1 · 2021-08-11 · Grant · Acquired 30,000 · Balance 30,000

F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",

F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

Class B Ordinary SharesSEC Table II · derivative / convertible securityDirect0 Reported balance After 2021-08-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2021-08-11 · Disposition to issuer · Disposed 30,000 · Balance 0

F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",

F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

Filing footnotes · ownership attribution and instrument terms

F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",

F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 05, 2024 Filed Jun 7, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 12,500 $0.00 Strike: $18.90 $0.00
Disclosure

SEC source: 0001415889-24-016058 · form4-06072024_060614.xml · derivative · entry 1

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2034-06-04

F1 · derivative.exercise_date: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 2,889 $13.49 Strike: $21.81 $38,972.61
Disclosure

SEC source: 0001415889-24-000706 · form4-01042024_060111.xml · derivative · entry 1

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,889

Underlying: Common Stock · 2,889 shares

Expires 2034-01-01

F1 · kind: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

F1 · derivative.exercise_date: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 12,500 $0.00 Strike: $16.30 $0.00
Disclosure

SEC source: 0001415889-23-009447 · form4-06082023_060614.xml · derivative · entry 1

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-05

F1 · derivative.exercise_date: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 6, 2024 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
January 19, 2023 Filed Jan 23, 2023 23:02 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 2,519 $15.48 Strike: $23.44 $38,994.12
Disclosure

SEC source: 0001415889-23-001334 · form4-01232023_110138.xml · derivative · entry 2

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,519

Underlying: Common Stock · 2,519 shares

Expires 2033-01-18

F2 · kind: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2023, the second installment vesting on June 30, 2023, the third installment vesting on September 30, 2023, and the fourth installment vesting on December 31, 2023.

F2 · derivative.exercise_date: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2023, the second installment vesting on June 30, 2023, the third installment vesting on September 30, 2023, and the fourth installment vesting on December 31, 2023.

Read SEC document
January 19, 2023 Filed Jan 23, 2023 23:02 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $23.44 $0.00
Disclosure

SEC source: 0001415889-23-001334 · form4-01232023_110138.xml · derivative · entry 1

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-01-18

F1 · derivative.exercise_date: This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on February 19, 2023.

Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:08 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 Disposition to issuerStock Option (Right to Buy) · Derivative 5,359 Not disclosed Strike: $3.63 Not disclosed
Disclosure

SEC source: 0001209191-23-001092 · doc4.xml · derivative · entry 4

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,359 shares

Expires 2032-06-05

F5 · price: Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.

F4 · derivative.exercise_date: This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.

Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:08 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 Disposition to issuerStock Option (Right to Buy) · Derivative 15,170 Not disclosed Strike: $14.25 Not disclosed
Disclosure

SEC source: 0001209191-23-001092 · doc4.xml · derivative · entry 3

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,170 shares

Expires 2031-07-30

F5 · price: Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.

F4 · derivative.exercise_date: This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.

Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:08 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 Disposition to issuerCommon Stock 8,198 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-001092 · doc4.xml · nonDerivative · entry 2

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · shares: This line item represents restricted stock units held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested restricted stock units was accelerated and each restricted stock unit was canceled in exchange for a cash payment equal to the Per Share Price less applicable tax withholdings.

F3 · price: This line item represents restricted stock units held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested restricted stock units was accelerated and each restricted stock unit was canceled in exchange for a cash payment equal to the Per Share Price less applicable tax withholdings.

Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:08 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 OtherCommon Stock 5,489 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-001092 · doc4.xml · nonDerivative · entry 1

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,198

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2)

F2 · price: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.

Read SEC document
June 06, 2022 Filed Jun 8, 2022 16:43 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 GrantStock Option (Right to Buy) · Derivative 5,359 $0.00 Strike: $3.63 $0.00
Disclosure

SEC source: 0001209191-22-035055 · doc4.xml · derivative · entry 2

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,359

Underlying: Common Stock · 5,359 shares

Expires 2032-06-05

F3 · derivative.exercise_date: The shares underlying the option vest as to one-twelfth (1/12th) of the shares on July 6, 2022 and monthly thereafter on the same day of the month as the grant date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date.

Read SEC document
June 06, 2022 Filed Jun 8, 2022 16:43 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 GrantCommon Stock 3,573 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-035055 · doc4.xml · nonDerivative · entry 1

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,687

F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

F2 · shares: The shares underlying the RSU will vest on June 6, 2023, but will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date.

Read SEC document
August 11, 2021 Filed Aug 13, 2021 19:39 UTC Surrozen, Inc./DE SRZN · Entity 6092 Disposition to issuerClass B Ordinary Shares · Derivative 30,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-033041 · doc4.xml · derivative · entry 2

Santel Donald J · CIK 0001293630 · Former Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 30,000 shares

Expires not disclosed

F1 · security: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",

F2 · security: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F1 · derivative.exercise_price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",

F2 · derivative.exercise_price: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F1 · derivative.exercise_date: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",

F2 · derivative.exercise_date: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F1 · derivative.expiration_date: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",

F2 · derivative.expiration_date: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

Read SEC document
August 11, 2021 Filed Aug 13, 2021 19:39 UTC Surrozen, Inc./DE SRZN · Entity 6092 GrantCommon Stock 30,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-033041 · doc4.xml · nonDerivative · entry 1

Santel Donald J · CIK 0001293630 · Former Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",

F2 · price: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

Read SEC document
July 30, 2021 Filed Aug 3, 2021 20:18 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 GrantStock Option (Right to Buy) · Derivative 4,765 $0.00 Strike: $14.25 $0.00
Disclosure

SEC source: 0001209191-21-049492 · doc4.xml · derivative · entry 4

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,765

Underlying: Common Stock · 4,765 shares

Expires 2021-07-30

F5 · derivative.exercise_date: One-eleventh (1/11th) of the Shares subject to the Option shall vest monthly beginning on August 7, 2021 and on the same day monthly thereafter, but will vest fully on the date of the Issuer's next annual meeting of stockholders held after the date of grant if not fully vested on such date, subject to the Reporting Person continuing to be a Service Provider through each such date.

Read SEC document
July 30, 2021 Filed Aug 3, 2021 20:18 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 GrantStock Option (Right to Buy) · Derivative 10,405 $0.00 Strike: $14.25 $0.00
Disclosure

SEC source: 0001209191-21-049492 · doc4.xml · derivative · entry 3

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,405

Underlying: Common Stock · 10,405 shares

Expires 2021-07-30

F4 · derivative.exercise_date: One-third (1/3) of the shares subject to the option shall vest on the 12 month anniversary of the grant date and the remainder will vest at one-twentyfourth (1/24th) per month thereafter (on the same day of the month as the grant date), subject to the Reporting Person continuing to be a Service Provider through each such date.

Read SEC document
July 30, 2021 Filed Aug 3, 2021 20:18 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 GrantCommon Stock 3,177 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-049492 · doc4.xml · nonDerivative · entry 2

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,114

F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

F3 · shares: These RSUs will vest on June 7, 2022, but will vest fully on the date of the Company's next annual meeting of stockholders held after the date of grant if not fully vested on such date, subject to the Reporting Person continuing to be a Service Provider through such date.

Read SEC document
July 30, 2021 Filed Aug 3, 2021 20:18 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 GrantCommon Stock 6,937 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-049492 · doc4.xml · nonDerivative · entry 1

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,937

F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

F2 · shares: These RSUs will vest over three years (on the same day of the month as the grant date) with one-third (1/3) vesting annually, in each case subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2019 Equity Incentive Plan (the "Plan")) through each such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.